Wilson H. Jr Miller
#141,017
Most Influential Person Now
Wilson H. Jr Miller's AcademicInfluence.com Rankings
Wilson H. Jr Millerphilosophy Degrees
Philosophy
#7361
World Rank
#10565
Historical Rank
Logic
#4417
World Rank
#5706
Historical Rank

Download Badge
Philosophy
Wilson H. Jr Miller's Degrees
- Doctorate Medicine Harvard University
- PhD Immunology Stanford University
Why Is Wilson H. Jr Miller Influential?
(Suggest an Edit or Addition)Wilson H. Jr Miller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) (4157)
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) (2647)
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) (2259)
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. (2015) (1780)
- Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML (1991) (1484)
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) (1425)
- Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). (1991) (1261)
- Role of the histone deacetylase complex in acute promyelocytic leukaemia (1998) (1126)
- Mechanisms of action of arsenic trioxide. (2002) (961)
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. (2020) (873)
- A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein (1994) (837)
- Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. (2004) (593)
- Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. (1992) (448)
- Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. (1993) (444)
- Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. (1998) (373)
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. (2017) (367)
- A review of cancer immunotherapy: from the past, to the present, to the future. (2019) (362)
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
- Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. (2008) (328)
- Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). (1995) (321)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
- Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. (1994) (292)
- All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study (1994) (288)
- Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. (1992) (275)
- Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. (2009) (266)
- Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. (1994) (255)
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (2010) (249)
- Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. (2014) (246)
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. (2008) (238)
- Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3 (2014) (218)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (216)
- Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. (2001) (204)
- Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. (1993) (201)
- CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. (1999) (199)
- The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. (1996) (197)
- Systemic cancer therapy: achievements and challenges that lie ahead (2013) (186)
- Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors (2009) (183)
- Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines (2003) (167)
- The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer (1998) (166)
- A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. (1997) (162)
- Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. (2015) (159)
- The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation (2014) (159)
- JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. (2004) (156)
- Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results (2015) (155)
- Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). (2016) (153)
- The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function (2003) (147)
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. (2019) (141)
- Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors (2013) (141)
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. (2018) (141)
- Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. (1994) (140)
- Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. (2013) (133)
- Moving towards personalized treatments of immune-related adverse events (2020) (132)
- Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. (2017) (127)
- Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors (2019) (126)
- Clinical and Molecular Characterization of a Rare Syndrome of Acute Promyelocytic Leukemia Associated With Translocation (2002) (123)
- Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. (2019) (119)
- 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. (1994) (115)
- Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells (2011) (115)
- Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer (2011) (114)
- An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). (2013) (109)
- Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. (2011) (104)
- Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. (2001) (102)
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (101)
- Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. (1995) (100)
- Arsenic trioxide: mechanisms of action. (2002) (96)
- Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. (2008) (95)
- Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo (2005) (95)
- 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. (1995) (89)
- Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. (1996) (86)
- Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 (2019) (85)
- High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial (2015) (81)
- Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. (1995) (80)
- Brain Erythropoietin Receptor Expression in Alzheimer Disease and Mild Cognitive Impairment (2007) (79)
- Molecular targets of arsenic trioxide in malignant cells. (2002) (79)
- Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. (1990) (77)
- Retinoic acid induces down-regulation of several growth factors and proto-oncogenes in a human embryonal cancer cell line. (1990) (76)
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (2022) (76)
- LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY (2014) (76)
- Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. (2005) (76)
- Nuclear insulin receptor substrate 1 interacts with estrogen receptor α at ERE promoters (2004) (74)
- Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score (2011) (73)
- Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (2015) (72)
- Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. (2015) (71)
- Retinoids inhibit measles virus through a type I IFN‐dependent bystander effect (2009) (68)
- Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. (2000) (68)
- Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. (2003) (67)
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (66)
- Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. (2002) (65)
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. (2017) (64)
- Retinoic acid mediates degradation of IRS-1 by the ubiquitin–proteasome pathway, via a PKC-dependant mechanism (2004) (64)
- Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) (64)
- Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils (2018) (63)
- Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. (2002) (63)
- Topoisomerase IIβ Negatively Modulates Retinoic Acid Receptor α Function: a Novel Mechanism of Retinoic Acid Resistance (2008) (61)
- Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. (1994) (61)
- A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. (2015) (61)
- A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E (2015) (60)
- Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. (2003) (59)
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. (2003) (59)
- Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. (1998) (58)
- Astroglial cytoprotection by erythropoietin pre‐conditioning: implications for ischemic and degenerative CNS disorders (2005) (58)
- Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. (2008) (58)
- Evaluation of denaturing high‐performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall‐cell lung cancer (2006) (57)
- MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma (2017) (57)
- Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. (2004) (57)
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy (2007) (56)
- 28-kDa Mammalian Heat Shock Protein, a Novel Substrate of a Growth Regulatory Protease Involved in Differentiation of Human Leukemia Cells (*) (1995) (55)
- Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers (2010) (55)
- Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling. (2006) (55)
- Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. (2014) (54)
- Oxalic acid excretion after intravenous ascorbic acid administration. (2009) (54)
- High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study (2020) (54)
- Retinoic acid causes a decline in TGF-alpha expression, cloning efficiency, and tumorigenicity in a human embryonal cancer cell line. (1990) (52)
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. (2019) (50)
- Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway (2003) (50)
- Arsenic trioxide decreases AKT protein in a caspase-dependent manner (2008) (50)
- Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. (2016) (49)
- Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. (2013) (46)
- Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. (1995) (46)
- In vivo analysis of the role of aberrant histone deacetylase recruitment and RARα blockade in the pathogenesis of acute promyelocytic leukemia (2006) (44)
- Trivalent Antimonials Induce Degradation of the PML-RAR Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells (1998) (43)
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study (2014) (43)
- Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK (2004) (43)
- A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group (2005) (42)
- Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. (1997) (41)
- Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. (2005) (41)
- H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. (2016) (41)
- 405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers (2007) (40)
- Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. (2014) (39)
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. (2019) (38)
- PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2020) (37)
- Aspartate 351 of Estrogen Receptor α Is Not Crucial for the Antagonist Activity of Antiestrogens* (2000) (37)
- The N-terminal of the estrogen receptor (ERα) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells (2003) (37)
- Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. (2009) (36)
- A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines (2008) (36)
- Predicted long‐term impact of COVID‐19 pandemic‐related care delays on cancer mortality in Canada (2021) (36)
- 1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM). (2014) (36)
- 1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma (2017) (36)
- Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma (2017) (32)
- Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation. (1990) (32)
- Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. (2009) (32)
- Differentiation induction as a treatment for hematologic malignancies (2002) (32)
- A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (31)
- Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies (2019) (30)
- Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells (1995) (30)
- RIG-I Is Required for the Inhibition of Measles Virus by Retinoids (2011) (30)
- Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis (2017) (30)
- Regulation of myeloblastin messenger RNA expression in myeloid leukemia cells treated with all-trans retinoic acid. (1993) (30)
- Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. (2017) (29)
- Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. (2004) (29)
- Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma (2009) (29)
- MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. (2019) (28)
- Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial (1993) (27)
- A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. (2011) (27)
- ERbeta sensitizes breast cancer cells to retinoic acid: evidence of transcriptional crosstalk. (2004) (26)
- Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. (2009) (26)
- Estrogen Receptor Expression Activates the Transcriptional and Growth-inhibitory Response to Retinoids without Enhanced Retinoic Acid Receptor α Expression (1998) (26)
- Translation of cancer immunotherapy from the bench to the bedside. (2019) (25)
- Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis (2013) (25)
- Arsenic Trioxide Overcomes Rapamycin-Induced Feedback Activation of AKT and ERK Signaling to Enhance the Anti-Tumor Effects in Breast Cancer (2013) (25)
- Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathways. (2008) (25)
- Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4 (2006) (24)
- Probing the pathobiology of response to all-trans retinoic acid in acute promyelocytic leukemia: premature chromosome condensation/fluorescence in situ hybridization analysis. (1996) (24)
- Adverse events associated with immune checkpoint inhibitor treatment for cancer (2019) (24)
- Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America (2008) (24)
- FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). (2020) (24)
- Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity (2007) (24)
- A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. (2017) (23)
- The Novel Arsenical Darinaparsin Is Transported by Cystine Importing Systems (2014) (23)
- Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. (2017) (23)
- A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (2017) (23)
- Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study. (2022) (23)
- A ribozyme which discriminates in vitro between PML/RAR alpha, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PML and RAR alpha, the transcripts from the nonrearranged alleles. (1994) (22)
- Spatially mapping the immune landscape of melanoma using imaging mass cytometry (2022) (22)
- Retinoic acid stimulates the protein kinase C pathway before activation of its beta-nuclear receptor during human teratocarcinoma differentiation. (1993) (22)
- Targeting PKCδ-mediated topoisomerase IIβ overexpression subverts the differentiation block in a retinoic acid-resistant APL cell line (2010) (21)
- High-dose vitamin C therapy: Renewed hope or false promise? (2006) (21)
- All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomas. (1994) (21)
- The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. (2015) (21)
- Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. (2007) (20)
- The effect of 13-cis-retinoic acid on wound healing in dogs. (1987) (20)
- Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer (2010) (20)
- Molecular cytogenetics of the acute promyelocytic leukemia‐derived cell line NB4 and of four all‐trans retinoic acid–resistant subclones (2002) (19)
- Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies (2011) (19)
- A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines (2009) (18)
- The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma (2020) (18)
- Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter (2007) (18)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (18)
- Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses. (2021) (18)
- Death by arsenic: implications of PML sumoylation. (2004) (17)
- The biology of acute promyelocytic leukemia (2001) (16)
- Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. (1995) (16)
- A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. (2003) (16)
- Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells. (2000) (16)
- 1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA. (2014) (16)
- A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. (2000) (16)
- Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression. (1998) (15)
- In vitro inhibition of mumps virus by retinoids (2013) (15)
- The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells (2013) (15)
- Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells (2017) (14)
- The PML / RARa ! Oncoprotein Is a Direct Molecular Target of Retinoic Acid in Acute Promyelocytic Leukemia Cells (2002) (14)
- The PML gene is linked to a megabase-scale insertion/deletion restriction fragment length polymorphism. (1995) (14)
- Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. (1992) (14)
- A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer. (2011) (13)
- Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell. (1993) (13)
- Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors (2018) (13)
- Retinoic acid and its rearranged receptor in the etiology and treatment of acute promyelocytic leukemia. (1992) (13)
- Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022). (2016) (13)
- Role of PML/RARα in the pathogenesis of APL (2006) (13)
- Expanding PML's functional repertoire through post-translational mechanisms. (2009) (13)
- Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy. (2011) (13)
- CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia. (1993) (13)
- Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. (2014) (12)
- Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
- Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid–sensitive and –resistant acute promyelocytic leukemia cells (2000) (12)
- The MNK1/2–eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer (2021) (12)
- Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors. (2004) (12)
- NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia. (2016) (12)
- Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer (2016) (12)
- PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade (2021) (11)
- The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity (2017) (11)
- Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition (2022) (11)
- Rexinoids Modulate Steroid and Xenobiotic Receptor Activity by Increasing Its Protein Turnover in a Calpain-dependent Manner* (2008) (11)
- Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365 (2012) (10)
- 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma (2015) (10)
- A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). (2020) (10)
- Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. (1994) (10)
- Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. (2014) (10)
- A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). (2014) (10)
- Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours (2013) (10)
- Pulsed-field gel electrophoresis analysis of retinoic acid receptor-α and promyelocytic leukemia rearrangements : detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia (1993) (10)
- An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. (2019) (10)
- Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors. (2006) (9)
- Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia. (1995) (9)
- An immunofluorescent assay for acute promyelocytic leukemia cells. (1998) (9)
- Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors (2021) (9)
- A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors (2019) (9)
- Molecular diagnosis and monitoring of acute promyelocytic leukemia treated with retinoic acid. (1994) (9)
- The Etiology of Acute Leukemia (2013) (8)
- Oncogenes and clinical oncology. (1991) (8)
- SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study (2021) (8)
- A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. (2019) (8)
- WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. (2018) (7)
- Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia. (2003) (6)
- Expanding the Use of Retinoids in Acute Myeloid Leukemia: Spotlight on Bexarotene (2008) (6)
- Retinoic acid and its rearranged receptor in the treatment of acute promyelocytic leukemia. (1993) (6)
- First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors (2022) (6)
- Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (6)
- Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient (2012) (6)
- Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in Canada (2022) (6)
- A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors (2016) (6)
- A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. (2020) (5)
- NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer (2001) (5)
- Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance (2021) (5)
- Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies (2005) (5)
- Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients (2021) (5)
- SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. (2003) (5)
- Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials (2014) (5)
- 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors (2020) (4)
- Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition (2020) (4)
- 795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 (2021) (4)
- Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. (2011) (4)
- Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma. (2022) (4)
- Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma. (2013) (4)
- Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy (2007) (4)
- Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit (2021) (3)
- Analysis of chromosome 12 abnormalities in male germ cell cancers. (1991) (3)
- Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. (2021) (3)
- Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements (2021) (3)
- Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. (2009) (3)
- Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results. (2016) (3)
- Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. (2022) (3)
- Predicted long-term impact of COVID-19 pandemic-related care delays on cancer incidence and mortality in Canada (2021) (3)
- Perioperative bevacizumab (Bev) containing chemotherapy for colorectal liver metastases (2008) (3)
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation (2021) (3)
- A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E, (2011) (3)
- Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report (2021) (3)
- Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy. (2019) (2)
- FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy (2022) (2)
- A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer. (2020) (2)
- 131I-LABELED M195 FOR MYELOID LEUKEMIAS (1994) (2)
- Abstract LB-171: A phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies (2010) (2)
- A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. (2013) (2)
- Cytokines and retinoic acid therapy for APL: new tricks from an old combination. (2004) (2)
- Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer. (2010) (2)
- Prostate-Specific Membrane Antigen in the Diagnosis of Prostatic Carcinoma (1995) (2)
- Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. (2022) (2)
- Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors (2017) (2)
- One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). (2015) (1)
- Abstract 491: Selective killing of oncogenically transformed cells by arsenic trioxide and trolox (2014) (1)
- Abstract 64: Quality and feasibility of a protocol for simultaneous isolation of RNA, DNA and tissue for IHC from needle core lymph node biopsies in DLBCL adapted for multi-center trials. (2013) (1)
- Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of human DLBCL cell lines towards an ABC-like phenotype. (2022) (1)
- 166 Ho and 90 Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188 Re radiolabel (2017) (1)
- Abstract 4707: Inhibition of autophagy overcomes acquired resistance to vorinostat (2012) (1)
- WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. (2017) (1)
- Mechanisms of Action of Arsenic Trioxide Updated (2002) (1)
- Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia. (1993) (1)
- Growth factors in human germ cell cancer. (1991) (1)
- In vitro inhibition of mumps virus by retinoids (2013) (1)
- Abstract A154: Inhibition of eIF4E with Ribavirin suppresses EMT and breast cancer invasiveness. (2013) (1)
- Resistance To Vorinostat In Hematological Malignancies May Involve Cytoprotective UPR and Correlates With Increased Sensitivity To Bortezomib-Induced Cell Death (2013) (1)
- 204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study (2008) (1)
- Abstract B235: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to vemurafenib in melanoma. (2013) (1)
- Molecular changes in epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) biopsies at time of progression compared to initial biopsy. (2016) (1)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (1)
- Abstract A53: Phosphorylation of eIF4E promotes phenotype switching and MDSC-mediated immunosuppression in melanoma (2020) (1)
- P4-249 Up-regulation of erythropoietin receptor expression in AD and MCI astroglia (2004) (1)
- Transcriptional repression of the rara pathyway is crucial for leukemogenesis (2000) (0)
- Phase II trial of sorafenib (S) and vinorelbine (V) in metastatic breast cancer (mBC) with pharmacokinetics (PK) analysis. (2012) (0)
- P3.07 Building the Organization Framework for Biopsy-Driven Translational Research: The Quebec Clinical Research Organization in Cancer (Q-Croc) Experience (2012) (0)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
- Abstract #5647: Enhancing mTORi efficacy by decreasing AKT feedback loop with arsenic trioxide (2009) (0)
- Abstract B83: Combination therapy with the histone deacetylase inhibitor panobinostat and the CD20-targeting antibody rituximab in diffuse large B-cell lymphoma. (2011) (0)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (0)
- Contents Vol. 78, 2010 (2010) (0)
- Epidermal growth factor receptor (EGFR) mutations detected by denaturing high performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC): Correlation with disease stage and response to tyrosine kinase inhibitors (TKI) therapy (2008) (0)
- 74. Cross-coupling between the retinoic acid (RA) and protein kinase C (PKC) pathways potentiates RA-mediated human teratocarcinoma (TC) differentiation (1992) (0)
- Epigenomic repression by APL oncoprotein (2008) (0)
- The MNK1/2-eIF4E axis drives melanoma plasticity, progression, and resistance to immunotherapy (2020) (0)
- P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma (2020) (0)
- Abstract 1696: Targeting EVI1-overexpressing AML with darinaparsin (2012) (0)
- Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in malignant cell lines (2005) (0)
- Abstract LB-100: Optimal modulation of DNA repair in CLL therapy (2010) (0)
- 264 POSTER A novel arsenical, darinaparsin, induces apoptosis in arsenic trioxide-resistant and MRP1/ABCC1-overexpressing cell lines (2008) (0)
- A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (2017) (0)
- Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors (2009) (0)
- Abstract 4890: Arsenic trioxide induces apoptosis through the activation of ASK1 and is enhanced by a thioredoxin reductase inhibitor (2012) (0)
- Abstract 5538: Development of HDACi resistance in DLBCL leads to a switch in subtype towards a more differentiated B-cell and is associated with increased sensitivity to proteasome inhibition (2014) (0)
- The pleiotropic effects of the MNK1/2-eIF4E axis support immune suppression and metastasis in a model of postpartum breast cancer (2020) (0)
- Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer. (2023) (0)
- Abstract 3710: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma (2014) (0)
- Subject Index Vol. 78, 2010 (2010) (0)
- Technology & tools development (2012) (0)
- Use of denaturing high performance liquid chromatography (dHPLC) for detection of EGFR mutations in patients with NSCLC. (2006) (0)
- Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation (2023) (0)
- Novel Transcriptional Interactions Between the Estrogen and Retinoic Acid Receptors in Human Breast Cancer Cells (2000) (0)
- The role of Ki-67 proliferation index vis-à-vis Oncotype DX. (2011) (0)
- Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2021) (0)
- Darinaparsin a Novel Organic Arsenic Molecule Active in Lymphoma: Development of An Oral Form. (2009) (0)
- apoptosis in APL and other malignant cell lines Trolox selectively enhances arsenic-mediated oxidative stress and (2013) (0)
- Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP). (2018) (0)
- Abstract A188: Proapoptotic versus prosurvival function of the MAP kinase p38 induced by HDAC inhibitor in hematological malignant cells (2009) (0)
- Abstract S12-01: High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia (2020) (0)
- Targeting EVI1-Overexpressing AML with Darinaparsin (2011) (0)
- Abstract 5360: Differential induction of the anti-oxidant response by arsenic trioxide and darinaparsin in leukemic cells (2011) (0)
- O-086 A phase III randomized trial of carboplati/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (0)
- A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: preliminary results of an ongoing prospective pilot study. (2007) (0)
- Supplemental Information NPM and BRG 1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia (2016) (0)
- A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1 (2013) (0)
- Abstract 686: MNK1 promotes the progression of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) (2016) (0)
- Prognostic significance of minimal residual disease detection and PML/RAR- a isoform type: long-term follow-up in acute promyelocytic leukemia (2001) (0)
- Abstract 2706: Phase 2 study with pharmacokinetics (PK) analysis of sorafenib and vinorelbine in metastatic breast cancer (2012) (0)
- Abstract 857: Anti-tumor and anti-metastatic activity of the eIF4E-targeted drug ribavirin in human and murine models of breast cancer. (2013) (0)
- Abstract A146: The role of cystine transport in darinaparsin‐induced cell death (2009) (0)
- 961P Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience (2020) (0)
- Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse (2021) (0)
- Uveal melanoma: Real-world analysis of immune checkpoint inhibitors efficacy and lymphocyte-to-monocyte ratio as a biomarker of response. (2022) (0)
- Abstract 2136: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors (2011) (0)
- Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene mutations detected by denaturing high-performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC) (2007) (0)
- Abstract 942: Decreasing the AKT feedback loop with arsenic trioxide enhances mTORi anti-tumor effects. (2013) (0)
- The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping review of systematic reviews and meta-analyses (2022) (0)
- Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors. (2018) (0)
- P19 A novel way of assessing health and vulnerability in older newly-diagnosed cancer patients: results of a pilot study (2009) (0)
- Abstract 5534: Building the organization framework for biopsy-driven translational research: The Quebec Clinical Research Organization in Cancer (Q-CROC) experience (2012) (0)
- Trolox Improves the Sensitivity of Multiple Myeloma to Arsenic Trioxide in Vitro and In Vivo. (2009) (0)
- 113. Reverse transcription polymerase chain reaction (RT-PCR) for the rearranged retinoic acid receptor-α (RAR-α) predicts response of acute promyelocytic leukemia (APL) to retinoic acid (RA) therapy and detects minimal residual disease (1992) (0)
- Author response: The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity (2017) (0)
- Abstract 288: TGF-beta induced epithelial-to-mesenchymal transition is attenuated when the MNK/eIF4E pathway is functionally impaired. (2013) (0)
- Abstract 5449: Histone deacetylase inhibitor treatment in B-cell non-Hodgkin's lymphoma - effect ofex vivotreatment on primary patient samples (2010) (0)
- Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM) (2015) (0)
- 171. Clinical and pharmacologic aspects of all-trans retinoic acid treatment in acute promyelocytic leukemia (1992) (0)
- RAPID COMMUNICATION Continuous Treatment With All-Trans Retinoic Acid Causes a Progressive Reduction in Plasma Drug Concentrations: Implications for Relapse and Retinoid “Resistance” in Patients With Acute Promyelocytic Leukemia (2003) (0)
- Abstract IA09: Translational control of the tumor microenvironment (2017) (0)
- 1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
- Darinaparsin:anovelorganic arsenicalwithpromising anticanceractivity (2009) (0)
- Abstract 3165: Anti-tumor activity of the eIF4E-targeted drug ribavirin in breast cancer cells (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Wilson H. Jr Miller?
Wilson H. Jr Miller is affiliated with the following schools: